News | 2009

May 6, 2009
MOSAIQUES and U.S. FDA describe detection of drug-induced side effects in early phase animal models
MOSAIQUES’ CE/MS technology paves the way for early assessment of drug-induced side effects and helps ensuring patient’s safety from the very beginning of preclinical research.
View Press Release        

May 5, 2009
Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using capillary electrophoresis coupled with mass spectrometry as a potential model for detection of drug-induced adverse effects
Our study strongly suggests that (drug-induced) nephrotoxicity can be detected with high accuracy in laboratory rodents using urinary proteome analysis. The effects observed are very similar to those seen in corresponding human diseases and similar approaches may be very helpful in evaluating drug-induced organ damage in preclinical animal models ...
View Publisher Website        

April 29, 2009
American Heart Association: Urine screening test may one day predict coronary artery disease
Proteome analysis, a screening requiring only a patient’s urine specimen, shows promise as a reliable and noninvasive way to diagnose atherosclerosis and coronary artery disease in the future, according to research presented at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009 ...
View Press Release        

February 20, 2009
MOSAIQUES and U.S. Food and Drug Administration (FDA) sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity
mosaiques diagnostics and therapeutics AG, a global leading proteomics innovations company, announces the signing of a collaborative agreement with the U.S. Food and Drug Administration.
View Press Release        

January 14, 2009
Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease
Abstract Background: In this study we sought to validate urinary biomarkers for diabetes and two common complications, coronary artery disease (CAD) and diabetic nephropathy (DN) …
View Abstract